Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans.
Variable amounts of flavin-containing monooxygenase isoforms 3 and 5 (FMO3 and FMO5) are present in microsomal preparations from adult, male, human liver. Quantitation with monospecific antibodies and recombinant isoforms as standards showed levels of FMO3 and of FMO5 that ranged from 12.5 to 117 and 3.5 to 34 pmol/mg microsomal protein, respectively. The concentration of FMO3 was greater than that of FMO5 in all samples, but the ratio of FMO3 to FMO5 varied from 2:1 to 10:1. Human hepatic microsomal samples also showed variable activities for the S-oxidation of methimazole. This activity was associated totally with FMO3; no participation of FMO5 was apparent. This conclusion was supported by several lines of evidence: first, the catalytic efficiency of FMO3 with methimazole was found to be approximately 5000 times greater than that of FMO5; second, the rate of metabolism showed a direct, quantitative relationship with FMO3 content; third, the plot of the relationship between metabolism and FMO3 content extrapolated close to the origin. A second reaction, the N-oxidation of ranitidine, exhibited a much higher Km with recombinant FMO3 than did methimazole (2 mM vs. 35 microM). However, a direct relationship between this reaction and FMO3 content in human hepatic microsomal preparations was also apparent. This result shows that even with a high Km substrate, FMO3-catalyzed metabolism can account for the majority of the product formation with some drugs. Our findings demonstrate that the contribution of FMO isoforms to human hepatic drug metabolism can be assessed quantitatively on the basis of the characteristics of the enzymes expressed in Escherichia coli.
Overby
L H
LH
Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
Carver
G C
GC
Philpot
R M
RM
D000328:Adult; D000906:Antibodies / Q000276:immunology; D000918:Antibody Specificity; D002384:Catalysis; D002927:Cimetidine / Q000378:metabolism; D004926:Escherichia coli / Q000201:enzymology; D006635:Histamine H2 Antagonists / Q000378:metabolism; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology*; D010105:Oxygenases / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D011899:Ranitidine / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism
D000906:Antibodies; D006635:Histamine H2 Antagonists; D007527:Isoenzymes; D012333:RNA, Messenger; D011994:Recombinant Proteins; D002927:Cimetidine; D011899:Ranitidine; D010105:Oxygenases; C020066:dimethylaniline monooxygenase (N-oxide forming)